DT&CRO Co

DT&CRO Co Debt/EBITDA

The Total Debt to EBITDA Ratio of DT&CRO Co (383930.KQ) as of Oct 16, 2026 is -2.55. In the previous year, Total Debt to EBITDA Ratio was -0.41 — a change of 514.03% (lower).

Debt/EBITDA

-2.55

YoY

514.03%

Last updated:

Total Debt to EBITDA Ratio of DT&CRO Co is 2024 -2.55 . Total Debt to EBITDA Ratio of DT&CRO Co was 2023 -0.41 . It decreases by 514.03% lower compared to the previous year.

The DT&CRO Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
18.99 KRW
Jan 1, 2020
3.16 KRW
Jan 1, 2022
-0.41 KRW
Jan 1, 2024
-2.55 KRW
The DT&CRO Co Debt/EBITDA history
YEARDebt/EBITDAYoY
-2.55+514.03%
-0.41-113.12%
3.16-83.34%
18.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DT&CRO Co Stock analysis

What does DT&CRO Co do? DT&CRO Co Ltd is a South Korean company operating in the Health Care sector, specifically within the Life Sciences Tools & Services industry. Based in Yongin, the company has 277 employees and completed its initial public offering (IPO) on November 11, 2022. DT&CRO Co Ltd provides non-clinical and clinical trial services for pharmaceuticals, medical devices, food, chemicals, and cosmetics. The company also offers analysis, efficacy evaluation, and related services. Its headquarters are located in Yongin, Gyeonggi-Do, South Korea. The company's website is www.dtncro.com. DT&CRO Co Ltd is engaged in research and development activities related to medicine and pharmaceuticals, though specific details about its R&D focus or product offerings are not provided in the available information. The company operates as a service provider in the life sciences sector, supporting various industries through trial services and analytical solutions. As a publicly traded company, it is listed under the ticker symbol 383930.KQ with ISIN KR7383930005. The company's operations are centered on delivering specialized services to clients in the pharmaceutical and related industries, emphasizing both non-clinical and clinical trial support. DT&CRO Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DT&CRO Co stock

Total Debt to EBITDA Ratio of DT&CRO Co is -2.55 in 2024.

Total Debt to EBITDA Ratio of DT&CRO Co changed from -0.41 to -2.55, representing a 514.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio DT&CRO Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's DT&CRO Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — DT&CRO Co

All Key Metrics — DT&CRO Co